Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: wherein A, L, R1, R2, R3, and n are described herein.
Type:
Grant
Filed:
April 9, 2021
Date of Patent:
September 12, 2023
Assignee:
Ariad Pharmaceuticals, Inc.
Inventors:
Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Xiaotian Zhu
Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
Type:
Grant
Filed:
May 12, 2021
Date of Patent:
July 12, 2022
Assignee:
ARIAD PHARMACEUTICALS, INC.
Inventors:
Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
Type:
Grant
Filed:
May 22, 2020
Date of Patent:
March 22, 2022
Assignee:
ARIAD PHARMACEUTICALS, INC.
Inventors:
Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
Type:
Grant
Filed:
May 12, 2021
Date of Patent:
December 7, 2021
Assignee:
ARIAD PHARMACEUTICALS, INC.
Inventors:
Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
Type:
Grant
Filed:
May 12, 2021
Date of Patent:
December 7, 2021
Assignee:
ARIAD PHARMACEUTICALS, INC.
Inventors:
Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
Type:
Grant
Filed:
May 12, 2021
Date of Patent:
December 7, 2021
Assignee:
ARIAD PHARMACEUTICALS, INC.
Inventors:
Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
Abstract: The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R1, R2, R3, R4, R5, R6, R16, R17, X1, X2, X3, X4, m, and n are described herein.
Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: (I) where A, L, R1, R2, R3, and n are described herein.
Type:
Grant
Filed:
December 14, 2017
Date of Patent:
September 14, 2021
Assignee:
Ariad Pharmaceuticals, Inc.
Inventors:
Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Yun Zhang, Xiaotian Zhu
Abstract: The invention relates to c-Kit inhibitors useful in the treatment of cancers, and other-threonine kinase mediated diseases, having the Formula: (I) wherein A, L, R1, R2, R3, and n are described herein.
Type:
Grant
Filed:
December 14, 2017
Date of Patent:
May 11, 2021
Assignee:
ARIAD PHARMACEUTICALS, INC.
Inventors:
Nicholas E. Bencivenga, David C. Dalgarno, Joseph M. Gozgit, Wei-Sheng Huang, Anna Kohlmann, Feng Li, Jiwei Qi, William C. Shakespeare, Ranny M. Thomas, Yihan Wang, Xiaotian Zhu
Abstract: Crystalline forms of brigatinib, pharmaceutical compositions comprising the same, and methods of their preparation and use of the same are disclosed herein.
Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
Type:
Grant
Filed:
September 28, 2018
Date of Patent:
May 26, 2020
Assignee:
Ariad Pharmaceuticals, Inc.
Inventors:
Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep K. Sharma
Abstract: Crystalline forms of brigatinib, pharmaceutical compositions comprising the same, and methods of their preparation and use of the same are disclosed herein.
Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
Type:
Grant
Filed:
May 13, 2015
Date of Patent:
March 12, 2019
Assignee:
ARIAD PHARMACEUTICALS, INC.
Inventors:
Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Dalgarno, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
Abstract: Novel crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide free base and 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, pharmaceutical compositions thereof and methods of their preparation and use are disclosed herein.
Type:
Grant
Filed:
November 2, 2016
Date of Patent:
November 13, 2018
Assignee:
Ariad Pharmaceuticals, Inc.
Inventors:
Christopher K. Murray, Leonard W. Rozamus, John J. Chaber, Pradeep Sharma
Abstract: The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of formula I: wherein the variables are as defined herein.
Type:
Grant
Filed:
May 4, 2012
Date of Patent:
December 5, 2017
Assignee:
ARIAD Pharmaceuticals, Inc.
Inventors:
David C. Dalgarno, Wei-Sheng Huang, William C. Shakespeare, Yihan Wang, Xiaotian Zhu
Abstract: This invention relates to compounds of the general formula (I): in which the variable groups are as identified herein, and to preparation and use of the compounds.
Type:
Grant
Filed:
March 13, 2014
Date of Patent:
December 5, 2017
Assignee:
ARIAD Pharmaceuticals, Inc.
Inventors:
Stephan G. Zech, Anna Kohlmann, Feng Li, Yihan Wang, Tianjun Zhou, David C. Dalgarno, William C. Shakespeare, Xiaotian Zhu
Abstract: The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula I: wherein the variables are as defined herein.
Type:
Grant
Filed:
February 16, 2016
Date of Patent:
December 5, 2017
Assignee:
ARIAD Pharmaceuticals, Inc.
Inventors:
Xiaotian Zhu, Yihan Wang, William C. Shakespeare, Wei-Sheng Huang, David C. Dalgarno
Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
Type:
Grant
Filed:
May 19, 2017
Date of Patent:
October 24, 2017
Assignee:
ARIAD Pharmaceuticals, Inc.
Inventors:
Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Dalgarno, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela V. West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
Abstract: The invention features a method for treating patients who have an ALK-driven cancer, which is, or has become, refractory to one or more of crizotinib, CH5424802 and ASP3026, or which bears an ALK mutation identified herein, by administering a compound of formula (I) to the patient. The invention also features methods, kits, and compositions for characterizing ALK-driven cancers to determine whether they express an ALK mutant.
Type:
Grant
Filed:
April 10, 2014
Date of Patent:
April 4, 2017
Assignee:
Ariad Pharmaceuticals, Inc.
Inventors:
Sen Zhang, William C. Shakespeare, Victor M. Rivera